

AMGEN'S HERITAGE IN NEPHROLOGY

Nearly 20 years in Canada
Founded in research,
cultivated through
Canadian clinical
experience¹

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia associated with chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis.²
Available August 2002

Sensipar® (cinacalcet hydrochloride) is indicated for the treatment of secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) receiving dialysis.³
Available August 2004




Pioneer in developing biologic medicines

In 1983, Amgen successfully cloned the erythropoietin gene from a single fragment of DNA among 1.5 million fragments of the human genome – resulting in the development of the first erythropoietin stimulating agent (ESA).¹

Manufacturing matters

>30 years of global experience in manufacturing and delivering biologic medicines. We aim to provide both quality and reliability of supply of our drugs, to support patients and the healthcare professionals who treat them. Amgen is proud to have a track record of zero supply shortages in Canada.¹



AT AMGEN, OUR MISSION IS TO SERVE PATIENTS



AMGEN'S HERITAGE IN NEPHROLOGY

AMGEN HAS INVESTED >30 YEARS
IN OUR MISSION TO SERVE PATIENTS
WITH CHRONIC KIDNEY DISEASE¹

GLOBALLY



- Over 50 Amgen-sponsored clinical trials
 - >30 interventional trials
 - >20 observational trials
- Estimated **>6.5 million** patients to date

IN CANADA



- Estimated **>500,000 patients** and **>11 million doses*** distributed to date
- No product supply shortages since founding of Amgen Canada
- A proud sponsor of national nephrology associations, including:
 - Canadian Society of Nephrology (CSN)
 - Kidney Foundation of Canada
 - Canadian Association of Nephrology Nurses and Technologists (CANNT)
 - Renal Pharmacists Network (RPN)
 - Canadian Association of Nephrology Social Workers (CANSW)
- Sponsorship of national and regional educational events for nephrology healthcare professionals
- Education and tools for nephrology healthcare professionals
- Patient education tools

¹ 1 pre-filled syringe=1 dose.

AMGEN HERITAGE TIMELINE AND SPONSORED PROGRAMS IN NEPHROLOGY¹

1980 

Amgen was founded in the US

1983 

Erythropoietin gene cloned by Amgen researchers

1989 

Epogen^{®†}
[AVAILABLE IN US JUNE 1989]⁴

Named Product of the Year by *Fortune* magazine

1991 

Amgen Canada Inc. is founded
Amgen Foundation is established: Giving back
• Focusing on excellence in science education to inspire the next generation of innovators
• Providing grants to non-profit organizations that reflect Amgen's core values and complement Amgen's dedication to support communities in innovative ways

1994 

Amgen wins the National Medal of Technology
• First biotech company to receive this award
• Recognized for leadership in developing new classes of therapeutics based on research and applications of cellular and molecular biology

2002

Aranesp[®] for treatment of CKD-associated anemia [AVAILABLE SINCE AUGUST 2002]

AIDe Patient Support Program launches

2004

Sensipar[®] for treatment of secondary hyperparathyroidism in patients with CKD receiving dialysis [AVAILABLE SINCE AUGUST 2004]

2003

Colloque DEVENIR begins
• An annual colloquium in Quebec for nephrology specialists

2008

PrevenirDevenir.com website created
• Amgen was the first sponsor and continues to provide ongoing support of this external education website

2009

UKidney education website
• Amgen was the first to provide sponsorship and provides ongoing support of this website

2010

Sponsorship of the Spice It Up! renal diet cookbooks⁶

2009 

Mercurius Project: Less frequent dosing of erythropoiesis stimulating agents in patients undergoing dialysis: A European multicentre cost study (2009)⁵

Building upon our nephrology heritage with ongoing investment to support those involved in furthering patient care

2016

Funding partner for Can-SOLVE CKD: Pan-Canadian patient-oriented kidney research network

2021

UKidney welcomed 1 million visitors to the site, thanks in part to the support of Amgen
Introduction of online and digital self-injection resources for patients on Aranesp[®]

Providing nearly 20 years of support to research and education for Canadian nephrology healthcare professionals and their patients



Please consult the Product Monograph at http://www.amgen.ca/Aranesp_PM.pdf for contraindications, warnings, precautions, adverse reactions, interactions, conditions of clinical use, and dosing (particularly regarding the administration of Aranesp® under the supervision of a healthcare professional, the longer serum half-life of Aranesp® compared to epoetin alfa, and the dosing and monitoring information when changing the route of administration) which have not been discussed in this piece.

The Product Monograph is also available by calling Amgen Canada Medical Information at 1-866-502-6436.

Please consult the Product Monograph at www.amgen.ca/Sensipar_PM.pdf for contraindications, warnings, precautions, adverse reactions, interactions, conditions of clinical use, and dosing (particularly regarding dose titration, serum calcium levels and PTH levels) which have not been discussed in this piece.

The Product Monograph is also available by calling Amgen Canada Medical Information at 1-866-502-6436.

CANNT=Canadian Association of Nephrology Nurses and Technologists;
CSN=Canadian Society of Nephrology; KFOC=Kidney Foundation of Canada

References: 1. Amgen Data on File. 2. Aranesp® (darbepoetin alfa) Product Monograph. Amgen Canada Inc. May 24, 2018. 3. Sensipar® (cinacalcet hydrochloride) Product Monograph. Amgen Canada Inc. October 11, 2019. 4. Food and Drug Administration. Information for Epogen/Procrit (Epoetin alfa). Available at: <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/information-epogenprocrit-epoetin-alfa>. Accessed October 20, 2020. 5. Burnier M, et al. Less frequent dosing of erythropoiesis stimulating agents in patients undergoing dialysis: a European multicentre cost study, *J Med Econ* 2009;12(2):77-86. 6. Spice It Up. Available at: <https://www.myspiceitup.ca/about-us/>. Accessed September 26, 2021. 7. Dialysis Outcomes and Practice Patterns Study (DOPPS). Support for the DOPPS Program. Available at: <https://www.dopps.org/AboutUs/Support.aspx>. Accessed October 19, 2020.

SC-IV
Aranesp®
(darbepoetin alfa)

AIDe
Program

Sensipar®
(cinacalcet hydrochloride)

© 2022 Amgen Canada Inc. All rights reserved.

Aranesp® and Sensipar® are registered trademarks of Amgen Inc., used with permission by Amgen Canada Inc.

ARA188E-22

